Table 2 Estimated cost inputs used in the model
From: Cost-effectiveness of sorafenib versus SBRT for unresectable advanced hepatocellular carcinoma
Cost input | Value | |
|---|---|---|
Cost administration and health States | ||
PFS per course | ||
Sorafenib | SBRT | |
Drug or treatment cost | 537,264 | 210,000 |
Costs of test: laboratory test, CT | 21,000 | 32,347 |
Costs of physician visit, dispensing fee, nursing care | 3000 | 0 |
Adverse events treatment | 38 | 16709 |
Sub-total | 563,365 | 259,056 |
PD per visit | ||
Costs of test: laboratory test, CT | 10,728 | 10,728 |
Costs of physician visit, dispensing fee, nursing care | 15,600 | 15,600 |
End of life care | 391,200 | 391,200 |
Sub-total | 417,528 | 417,528 |